Enterprise Value
409.1B
Cash
36.41B
Avg Qtr Burn
N/A
Short % of Float
0.19%
Insider Ownership
0.01%
Institutional Own.
8.22%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Etavopivat (FT-4202) (PKR activator) Details Sickle cell disease | Phase 2/3 Data readout | |
FT-7051 (CBP/P300 inhibitor) Details Castration-resistant prostate cancer | Failed Discontinued |